NYSE:ABTMedical Equipment
Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors
In late May and early June 2026, Abbott highlighted new data showing rising, often-missed diabetic ketoacidosis cases and secured CE Mark approval in Europe for Libre Duo and Libre Duo 10 Day, its first-of-its-kind dual glucose‑ketone continuous monitoring systems, while awaiting U.S. FDA clearance.
The combination of alarming national trends in DKA-related hospitalizations and Abbott’s dual-analyte sensor positions the company to address a critical gap in diabetes care.
We’ll now examine...